Outcomes following neoadjuvant chemotherapy for breast cancer: pathological response in the axilla
Association of Breast Surgery ePoster Library. McLean R. 05/13/19; 257059; P015
Mr. Ross McLean
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
P015
Topic: Axilla
Introduction: Neoadjuvant chemotherapy (NAC) is used effectively in the management of breast cancer, and can downstage axillary disease. This study aimed to evaluate downstaging of axillary disease in 'real world' practice. Methods Retrospective data analysis from two breast screening institutions, including all patients with axillary disease, undergoing NAC between May 2014-November 2017. Positive axillary nodes were defined as the presence of macrometastases on pathology. Results: A total of 136 patients were included, with 76 axillary node clearances (ANC,55.9%), 25 axillary node dissections/sampling (18.4%) and 35 sentinel lymph node biopsies (SLNB,25.7%). In the ER+/HER2- group, the complete pathological response (pCR) rate was poor at 19.2%. All other molecular subgroups had a pCR rate of >50%. Follow-on ANC were performed in 3 patients (2%) with positive SLNB and axillary radiotherapy was given to 49 patients (28%).Table 1: Pathological Response Axilla,n(%)*Hormonal Receptor StatusComplete pathological responsePartial pathological responseNo responseProgressionTotalER-/HER2-18 (56.3)7 (21.9)6 (18.8)1 (3.1)32 (23.5)ER-/HER2+22 (66.7)6 (18.2)2 (6.1)3 (9.1)33 (24.3)ER+/HER2-5 (19.2)12 (46.2)5 (19.2)4 (15.4)26 (19.1)ER+/HER2+25 (55.6)14 (31.1)1 (2.2)
Topic: Axilla
Introduction: Neoadjuvant chemotherapy (NAC) is used effectively in the management of breast cancer, and can downstage axillary disease. This study aimed to evaluate downstaging of axillary disease in 'real world' practice. Methods Retrospective data analysis from two breast screening institutions, including all patients with axillary disease, undergoing NAC between May 2014-November 2017. Positive axillary nodes were defined as the presence of macrometastases on pathology. Results: A total of 136 patients were included, with 76 axillary node clearances (ANC,55.9%), 25 axillary node dissections/sampling (18.4%) and 35 sentinel lymph node biopsies (SLNB,25.7%). In the ER+/HER2- group, the complete pathological response (pCR) rate was poor at 19.2%. All other molecular subgroups had a pCR rate of >50%. Follow-on ANC were performed in 3 patients (2%) with positive SLNB and axillary radiotherapy was given to 49 patients (28%).Table 1: Pathological Response Axilla,n(%)*Hormonal Receptor StatusComplete pathological responsePartial pathological responseNo responseProgressionTotalER-/HER2-18 (56.3)7 (21.9)6 (18.8)1 (3.1)32 (23.5)ER-/HER2+22 (66.7)6 (18.2)2 (6.1)3 (9.1)33 (24.3)ER+/HER2-5 (19.2)12 (46.2)5 (19.2)4 (15.4)26 (19.1)ER+/HER2+25 (55.6)14 (31.1)1 (2.2)
P015
Topic: Axilla
Introduction: Neoadjuvant chemotherapy (NAC) is used effectively in the management of breast cancer, and can downstage axillary disease. This study aimed to evaluate downstaging of axillary disease in 'real world' practice. Methods Retrospective data analysis from two breast screening institutions, including all patients with axillary disease, undergoing NAC between May 2014-November 2017. Positive axillary nodes were defined as the presence of macrometastases on pathology. Results: A total of 136 patients were included, with 76 axillary node clearances (ANC,55.9%), 25 axillary node dissections/sampling (18.4%) and 35 sentinel lymph node biopsies (SLNB,25.7%). In the ER+/HER2- group, the complete pathological response (pCR) rate was poor at 19.2%. All other molecular subgroups had a pCR rate of >50%. Follow-on ANC were performed in 3 patients (2%) with positive SLNB and axillary radiotherapy was given to 49 patients (28%).Table 1: Pathological Response Axilla,n(%)*Hormonal Receptor StatusComplete pathological responsePartial pathological responseNo responseProgressionTotalER-/HER2-18 (56.3)7 (21.9)6 (18.8)1 (3.1)32 (23.5)ER-/HER2+22 (66.7)6 (18.2)2 (6.1)3 (9.1)33 (24.3)ER+/HER2-5 (19.2)12 (46.2)5 (19.2)4 (15.4)26 (19.1)ER+/HER2+25 (55.6)14 (31.1)1 (2.2)
Topic: Axilla
Introduction: Neoadjuvant chemotherapy (NAC) is used effectively in the management of breast cancer, and can downstage axillary disease. This study aimed to evaluate downstaging of axillary disease in 'real world' practice. Methods Retrospective data analysis from two breast screening institutions, including all patients with axillary disease, undergoing NAC between May 2014-November 2017. Positive axillary nodes were defined as the presence of macrometastases on pathology. Results: A total of 136 patients were included, with 76 axillary node clearances (ANC,55.9%), 25 axillary node dissections/sampling (18.4%) and 35 sentinel lymph node biopsies (SLNB,25.7%). In the ER+/HER2- group, the complete pathological response (pCR) rate was poor at 19.2%. All other molecular subgroups had a pCR rate of >50%. Follow-on ANC were performed in 3 patients (2%) with positive SLNB and axillary radiotherapy was given to 49 patients (28%).Table 1: Pathological Response Axilla,n(%)*Hormonal Receptor StatusComplete pathological responsePartial pathological responseNo responseProgressionTotalER-/HER2-18 (56.3)7 (21.9)6 (18.8)1 (3.1)32 (23.5)ER-/HER2+22 (66.7)6 (18.2)2 (6.1)3 (9.1)33 (24.3)ER+/HER2-5 (19.2)12 (46.2)5 (19.2)4 (15.4)26 (19.1)ER+/HER2+25 (55.6)14 (31.1)1 (2.2)
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}